Oelschlager Kristen M's Form 4 filing
Castle Biosciences IncCSTL · filed Oct 5, 2026
- Accession no.
- 0001628280-26-064912
- Filed
- Oct 5, 2026, 4:07 PM ET
- Trade date
- Oct 1, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $149.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Oelschlager Kristen MCIK 0001856565 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Common Stock | MOption exerciseAcquired | +4,153 | $3.38 | +$14,037.14 | 17,509 | Direct | |
| Oct 1, 2026 | Common Stock | SSaleDisposed | −2,807 | $35.75F2 | −$100,350.25 | 14,702 | Direct | |
| Oct 1, 2026 | Common Stock | SSaleDisposed | −1,346 | $36.38F3 | −$48,967.48 | 13,356 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Common Stock | MOption exerciseDisposed | −4,153 | $0.00 | $0 | 8,305 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $35.21 to $36.19, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $36.21 to $36.78, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.